检索
AI 对话
analysis
趋势分析
编组
开放平台
more
更多
排名必读论文期刊顶会热点AI 简史溯源树小脉星探人才迁徙塔尖人才国防情报追踪开源工具智慧手语
VIPCreated with Sketch.

Lacutamab in patients (pts) with advanced mycosis fungoides (MF) according to KIR3DL2 expression: early results from the TELLOMAK phase 2 trial

Martine Bagot, Youn Kim,Pier Luigi Zinzani,Stephane Dalle,Marie Beylot-Barry,Pablo L. Ortiz-Romero,Andrea Cambalia,Olivier Dereure,Laurent Mortier,Eric Jacobsen,Maxime Battistella,Alejandro Gru,Helene Moins-Teisserenc,Christine Paiva,Agnes Boyer-Chammard,Federico Rotolo,Hatem A. Azim,Pierluigi Porcu

EUROPEAN JOURNAL OF CANCER（2021）

引用 1|浏览12
暂无评分
关键词
Mycosis fungoides, lacutamab, KIR3DL2 expression, killer immunoglobulin-like receptor, TELLOMAK
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要